Home » Business » Manufacturing
Healthcare spending may double
By Feng Jianmin |
April 17, 2013, Wednesday
|
Print Edition
Print Edition
CHINA'S healthcare spending may nearly double in the next three years and pharmaceutical merger and acquisition activities are set to grow in the world's second largest market for such deals, an industry report said yesterday.
By 2015, healthcare expenditure on pharmaceuticals, medical devices, distribution, hospitals, pharmacies and insurance will account for 10 percent of the country's gross domestic product, an increase from nearly 6 percent by the end of 2012, according to the report.
Norbert Meyring, head of KPMG Life Science in China and Asia-Pacific, attributed the increase in spending to robust economic growth, the rising middle class as well as government support, urbanization demand and people's increasing awareness for quality healthcare.
KPMG predicted pharmaceutical M&A activities in China to grow along with the expansion in the market.
Between 2011 and 2012, China registered 132 pharmaceuticals transactions worth US$5.2 billion, surpassing Germany and Japan by both deal number and value, and only lagging the United States as the second largest pharmaceutical M&A market.
By 2015, healthcare expenditure on pharmaceuticals, medical devices, distribution, hospitals, pharmacies and insurance will account for 10 percent of the country's gross domestic product, an increase from nearly 6 percent by the end of 2012, according to the report.
Norbert Meyring, head of KPMG Life Science in China and Asia-Pacific, attributed the increase in spending to robust economic growth, the rising middle class as well as government support, urbanization demand and people's increasing awareness for quality healthcare.
KPMG predicted pharmaceutical M&A activities in China to grow along with the expansion in the market.
Between 2011 and 2012, China registered 132 pharmaceuticals transactions worth US$5.2 billion, surpassing Germany and Japan by both deal number and value, and only lagging the United States as the second largest pharmaceutical M&A market.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
